LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone for DCISionRT®, its validated genomic test that provides individualized recurrence risk assessment and predicts…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
